Navigation Links
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
Date:11/10/2008

period ended

September 30 September 30

-------------------------------------------------------------------------

Consolidated

Statements

of Operations 2008 2007 2008 2007

-------------------------------------------------------------------------

-------------------------------------------------------------------------

(unaudited) (unaudited) (unaudited) (unaudited)

Revenues:

Gross sales $ 206 $ - $ 206 $ -

Discounts, returns

and cooperative

promotional

incentives (53) - (53) -

-------------------------------------------------------------------------

Net sales 153 - 153 -

Collaboration

agreement - 228 205 913

Reimbursable costs - 73 69 332

-------------------------------------------------------------------------

153 301 427 1,245

-------------------------------------------------------------------------

Expenses:

Research and

development 5,208 11,964 21,111 43,533

Research tax

credits and

grants (264) (434) (1,128) (1,434)

-------------------------------------------------------------------------

4,944 11,530 19,983 42,099

General and

administrative 2,987 2,559 8,513 9,184

Marketing and

selling 1,424 - 3,459 -

Reimbursable costs -
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
2. BELLUS Health provides update on activities
3. BELLUS Health announces closing of Innodia acquisition
4. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
5. BELLUS HEALTH reports results for first quarter of fiscal 2008
6. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
7. Healthcare Realty Trust Announces Third Quarter Results
8. World Publics See Government as Responsible for Ensuring Basic Healthcare, Food, and Education Needs
9. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
10. Major Mental Health Associations Join to Support Give an Hour
11. Wyeth to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 2Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 3Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 4Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 5Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 6Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 7Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 8Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 9Health News:Thermage Announces Fourth Quarter and Full Year 2007 Financial Results 10Health News:Eyes a Window to Hearing Loss? 2Health News:Eyes a Window to Hearing Loss? 3Health News:Americans Believe Pettitte had Conversations with Clemens Regarding Both Players' Use of HGH 2Health News:Women who suffered child abuse spend more on health care 2Health News:Women who suffered child abuse spend more on health care 3Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 2Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 3
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5GreenHouse Energy Governor Schwarzenegger Join in Driving the Future of Fueling in California 12478 1GreenHouse Energy Governor Schwarzenegger Join in Driving the Future of Fueling in California 12478 2GreenHouse Energy Governor Schwarzenegger Join in Driving the Future of Fueling in California 12478 3PLC Systems Announces Appointment of Louis Brenner M D to Board of Directors 48005 1PLC Systems Announces Appointment of Louis Brenner M D to Board of Directors 48005 2Global Testing Shows No Variation in Swine Flu Virus 48002 1Global Testing Shows No Variation in Swine Flu Virus 48002 2Global Testing Shows No Variation in Swine Flu Virus 48002 3Global Testing Shows No Variation in Swine Flu Virus 48002 4Global Testing Shows No Variation in Swine Flu Virus 48002 5Global Testing Shows No Variation in Swine Flu Virus 48002 6Global Testing Shows No Variation in Swine Flu Virus 48002 7Global Testing Shows No Variation in Swine Flu Virus 48002 8Global Testing Shows No Variation in Swine Flu Virus 48002 9Global Testing Shows No Variation in Swine Flu Virus 48002 10Global Testing Shows No Variation in Swine Flu Virus 48002 11